Integral Expands Cryptocurrency Market Data Services to Include 14 Cryptocurrencies and 16 Exchanges
Integral (www.integral.com ), the financial technology partner trusted by leading banks, brokers, and investment managers to design, deliver and grow their FX businesses, announced today that it has expanded its market data offering for cryptocurrencies to include 14 major cryptocurrencies connecting to all major exchange sources across the U.S., Europe and Asia including Japan and Hong Kong.
“An accurate, stable, and reliable reference price is a requirement for any market maker,” said Harpal Sandhu, CEO of Integral . “The Cryptocurrency Market Data Service connects to the most price sources and applies the most advanced price discovery algorithm available.”
Integral has years of experience as a technology leader and innovator in foreign exchange and is now applying this ingenuity to the cryptocurrency market. The Market Data Service uses algorithms developed with Stanford University for Integral FX Benchmark to provide the most precise reference prices for cryptocurrencies.
“Integral’s Cryptocurrency Market Data has proven to be the most stable and most accurate price source for our market making service, especially in times of extreme volatility,” said Charalambos Psimolophitis, CEO of FxPro Group . “We will continue to expand our market leading position with additional product offerings based on this reliable platform.”
In the coming weeks, the Market Data Service will also make available a real-time consolidated order book across all 16 exchanges via its high-performance market data network in NY4, LD4 and TY3.
Integral offers a variety of configurations of currency pairs and exchanges starting at US$1700/month.
For more information, visit https://www.integral.com/market_data/cryptocurrency_market_data.html
Integral is a financial technology company that helps its customers—banks, brokers, and asset managers—outperform their competition in the foreign exchange market through innovative solutions for workflow management and advanced execution. This powerful cloud-based platform is the industry’s only answer for FX institutions that want to design and deliver complete solutions tailored to their businesses. Integral’s modern approach of addressing the entire FX lifecycle with an intelligent platform allows its customers to achieve the lowest transaction costs, greatest operational efficiency, and highest yield. Founded in 1993, Integral maintains development, support, and sales offices in Palo Alto, New York, London, Tokyo, Singapore and Bangalore.
Additional information is available at http://www.integral.com
©2017 Integral Development Corp. All rights reserved. Integral technology is protected under U.S. Patent Nos. 6,347,307; 7,882,011; 8,417,622; 8,862,507, 9,412,134: 9,836,789, and patent pending applications and related intellectual property.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
DE-INCYTE21.10.2018 12:47 | pressemeddelelse
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma
SERVIER21.10.2018 11:12 | pressemeddelelse
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer
IL-GILEAD-SCIENCES21.10.2018 00:32 | pressemeddelelse
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting
CA-TRUE-RELIGION19.10.2018 19:39 | pressemeddelelse
Manchester United and True Religion Launch Denim Range
ARCH-INSURANCE19.10.2018 15:12 | pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum